ARTICLE | Data Byte
How 89bio’s Phase IIb NASH data match up with Akero’s in FGF21 class
Planned Phase III trials would clarify benefit compared with other classes ahead in regulatory queue
March 22, 2023 10:20 PM UTC
New Phase IIb data for 89bio’s pegozafermin strengthen the case for the therapy’s class to treat NASH, even if the biotech’s therapy reaches the market behind its competitors.
89bio Inc. (NASDAQ:ETNB) will need to conduct Phase III testing to further illuminate how pegozafermin could differentiate from other FGF21 programs in the hotly contested field of non-alcoholic steatohepatitis treatments...